{
  "id": "fda_guidance_chunk_0769",
  "title": "Introduction - Part 769",
  "text": "B. SCOPE AND DIRECTION (1.2).....................................................................................................................................2 II. CONSIDERATIONS FOR OVERALL CLINICAL DEVELOPMENT.................................................................4 A. TRIAL CONTEXT (2.1)................................................................................................................................................4 B. SCOPE OF TRIALS (2.2) .............................................................................................................................................6 C. DESIGN TECHNIQUES TO AVOID BIAS (2.3).............................................................................................................10 III. TRIAL DESIGN CONSIDERATIONS...................................................................................................................14 A. DESIGN CONFIGURATION (3.1)................................................................................................................................14 B. MULTICENTER TRIALS (3.2) ....................................................................................................................................16 C. TYPE OF COMPARISON (3.3)....................................................................................................................................18 D. GROUP SEQUENTIAL DESIGNS (3.4).........................................................................................................................21 E. SAMPLE SIZE (3.5) ...................................................................................................................................................21 F. DATA CAPTURE AND PROCESSING (3.6)...................................................................................................................23 IV. TRIAL CONDUCT CONSIDERATIONS..............................................................................................................23 A. TRIAL MONITORING AND INTERIM ANALYSIS (4.1) .................................................................................................23 B. CHANGES IN INCLUSION AND EXCLUSION CRITERIA (4.2)........................................................................................24 C. ACCRUAL RATES (4.3) ............................................................................................................................................24 D. SAMPLE SIZE ADJUSTMENT (4.4) .............................................................................................................................24 E. INTERIM ANALYSIS AND EARLY STOPPING (4.5) ......................................................................................................24 F. ROLE OF INDEPENDENT DATA MONITORING COMMITTEE (IDMC) (4.6) ...............................................................26 V. DATA ANALYSIS CONSIDERATIONS................................................................................................................27 A. PRESPECIFICATION OF THE ANALYSIS (5.1) .............................................................................................................27 B. ANALYSIS SETS (5.2) ..............................................................................................................................................27 C. MISSING VALUES AND OUTLIERS (5.3)....................................................................................................................31 D. DATA TRANSFORMATION (5.4)................................................................................................................................31 E. ESTIMATION, CONFIDENCE INTERVALS, AND HYPOTHESIS TESTING (5.5) ..............................................................32 F. ADJUSTMENT OF SIGNIFICANCE AND CONFIDENCE LEVELS (5.6).............................................................................33 G. SUBGROUPS, INTERACTIONS, AND COVARIATES (5.7) .............................................................................................33 H. INTEGRITY OF DATA AND COMPUTER SOFTWARE VALIDITY (5.8).............................................................................34 VI. EVALUATION OF SAFETY AND TOLERABILITY.......................................................................................34 A. SCOPE OF EVALUATION (6.1)...................................................................................................................................34 B. CHOICE OF VARIABLES AND DATA COLLECTION (6.2) .............................................................................................34 C. SET OF SUBJECTS TO BE EVALUATED AND PRESENTATION OF DATA (6.3) ...............................................................35 D. STATISTICAL EVALUATION (6.4)..............................................................................................................................36 E. INTEGRATED SUMMARY (6.5)...................................................................................................................................37 VII. REPORTING.......................................................................................................................................................37 A. EVALUATION AND REPORTING (7.1) ........................................................................................................................37 B. SUMMARIZING THE CLINICAL DATABASE (7.2) .........................................................................................................39 GLOSSARY (ANNEX 1) ...................................................................................................................................................41 GUIDANCE FOR INDUSTRY1 E9 Statistical Principles for Clinical Trials I. INTRODUCTION A. Background and Purpose (1.1) 2 The efficacy and safety of medicinal products should be demonstrated by clinical trials that follow the guidance in E6 Good Clinical Practice: Consolidated Guidance adopted by the ICH, May 1, 1996. The role of statistics in clinical trial design and analysis is acknowledged as essential in that ICH guidance. The proliferation of statistical research in the area of clinical trials coupled with the critical role of clinical research in the drug approval process and health care in general necessitate a succinct document on statistical issues related to clinical trials. This guidance is written primarily to attempt to harmonize the principles of statistical methodology applied to clinical trials for marketing applications submitted in Europe, Japan and the United States. As a starting point, this guidance utilized the CPMP (Committee for Proprietary Medicinal Products) Note for Guidance entitled Biostatistical",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 1032192,
  "end_pos": 1033728,
  "tokens": 512,
  "tags": [
    "safety",
    "efficacy",
    "design",
    "statistical",
    "regulatory",
    "clinical_trial",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.737Z"
}